Guest Eden Raheem highlights six biotech stocks, favoring value plays over overvalued AI narratives.
Summary
Eden Raheem of Next Edge Capital argues biotech is entering a new bull market, driven by rate sensitivity and long-duration cash flows. He identifies six specific stocks, including Cytokinetics, Legend Biotech, TG Therapeutics, Alpha Cognition, ClearPoint Neuro, and Nectar Therapeutics, citing specific valuation gaps and clinical data. Conversely, he advises against buying Moderna, citing overvaluation and limited market size despite recent AI-driven rallies. The discussion emphasizes the sector's sensitivity to interest rates and the importance of comparing public valuations to recent private M&A transactions.
Episode sections
- 0:00 – 1:27
Intro and Sponsor Read
Fictional sponsor read for Alpine Credits and introduction of guest Eden Raheem.
- 1:27 – 3:57
Biotech Market Cycle and Rate Sensitivity
Discussion on biotech entering a new bull market and its sensitivity to interest rates due to long-duration cash flows.
- 3:57 – 5:10
Stock 1: Cytokinetics
Analysis of Cytokinetics' heart drug sales and valuation discount following failed Novartis acquisition talks.
- 5:10 – 8:14
Stock 2: Legend Biotech
Comparison of Legend Biotech's valuation to competitors and recent private M&A activity.
- 8:14 – 9:28
Stock 3: TG Therapeutics
Review of TG Therapeutics' revenue growth for Briumvi and potential market expansion from subcutaneous dosing.
- 9:28 – 10:47
Stock 4: Alpha Cognition
Discussion of Alpha Cognition's reformulated Alzheimer's drug and revenue projections.
- 10:47 – 12:47
Stock 5: Moderna
Critique of Moderna's valuation and market size despite AI-driven stock surge.
- 12:47 – 18:50
Stock 6: ClearPoint Neuro and Nectar Therapeutics
Analysis of ClearPoint Neuro's procedural revenue potential and Nectar Therapeutics' alopecia clinical data.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ | equity | neutral | Legend makes a cancer treatment with Johnson Johnson. |
| NEKTAR THERAPEUTICSNKTR | equity | bullish | And stock number six, Nectar Therapeutics. It's testing a new atopic dermatitis treatment. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Biotech peaked in summer 2015, had another peak in early 2021, and fell 70% over the next four years, ending in a crescendo in April 2025.
Eden Raheem ·1:27
How to verify: Check historical biotech index performance data (e.g., XBI) for peaks in 2015 and 2021 and the 70% decline period through April 2025.
Cytokinetics stock surged from $35 to mid-80s after Phase 3 data, then to ~$110 on Novartis rumors, before falling after management held out for $145.
Eden Raheem ·4:16
How to verify: Review Cytokinetics (CYTK) stock price history and press releases regarding Phase 3 obstructive HCM data and Novartis acquisition rumors from three years prior.
Legend Biotech sales are on pace for $1.4 billion this year.
Eden Raheem ·5:19
How to verify: Check Legend Biotech (LEGN) quarterly earnings reports and company guidance for current year sales projections.
Gilead acquired AcelRx for eight billion dollars.
Eden Raheem ·5:59
How to verify: Review SEC filings or press releases confirming Gilead Sciences' acquisition of AcelRx Pharmaceuticals for $8 billion.
Eli Lilly acquired private company Kelowna for plus three billion dollars plus another four billion in bio bucks.
Eden Raheem ·7:54
How to verify: Check Eli Lilly (LLY) press releases or SEC filings regarding the acquisition of Kelowna Biotechnology for $3 billion upfront and $4 billion in milestones.
TG Therapeutics has grown at basically 100% revenue growth every year for three years.
Eden Raheem ·8:38
How to verify: Review TG Therapeutics (TGTX) annual revenue reports for the past three fiscal years to verify year-over-year growth rates.
Moderna hit $500 a share and a market cap approaching $200 billion five years ago, then fell 95% to $25 a share.
Eden Raheem ·11:02
How to verify: Check Moderna (MRNA) historical stock price data for the peak near $500 and the subsequent decline to $25 over a five-year period.
Moderna's short interest got to 70 million shares, making it a more shorted S&P 500 stock.
Eden Raheem ·11:21
How to verify: Check FINRA short interest data or Nasdaq short interest reports for Moderna (MRNA) to verify the 70 million share short position.
Nectar Therapeutics' alopecia drug showed 63% of patients achieving SALT scores below 20 six months after stopping treatment, compared to a 20% standard of care.
Eden Raheem ·15:53
How to verify: Review Nectar Therapeutics (NCTD) clinical trial data presentations or press releases regarding Phase 2/3 alopecia data and SALT score outcomes.
Big Pharma faces a patent cliff with over $100 billion of revenues between now and 2030 that are going to lose patent coverage.
Eden Raheem ·17:05
How to verify: Review industry reports from IQVIA or EvaluatePharma on projected patent expirations and revenue losses for major pharmaceutical companies through 2030.
Do your own research
- Verify Cytokinetics' current stock price and any recent M&A rumors or filings regarding Novartis.
- Compare Legend Biotech's enterprise value to Eli Lilly's acquisition terms for Kelowna in SEC filings.
- Review TG Therapeutics' quarterly earnings reports for Briumvi sales growth and market share data versus Roche.
- Check Alpha Cognition's 10-K or 10-Q filings for revenue projections and reformulation clinical trial results.
- Analyze Moderna's short interest data and market size estimates for its cancer vaccine indications.
- Confirm ClearPoint Neuro's revenue model and pending regulatory status for Unicure's Huntington's treatment.
- Review Nectar Therapeutics' clinical trial data for alopecia, specifically SALT score outcomes and response rates.
Full transcriptexpand
- 0:00
- Unidentified speaker: Breaking story from Alpine News Network!
- 0:02
- Unidentified speaker: Sandra and Kabir are celebrating 50 years of marriage by turning their boring bedroom into a spicy one.
- 0:09
- Unidentified speaker: Oh my!
- 0:10
- Unidentified speaker: Alpine Credits sent a super strength hero to help with a home renovation loan.
- 0:15
- Unidentified speaker: New floors, windows, a heart-shaped button that plays this tune.
- 0:21
- Unidentified speaker: Okay, I think that's quite enough.
- 0:23
- Unidentified speaker: Own your home, need a loan?
- 0:24
- Unidentified speaker: Alpine Credits can help.
- 0:26
- Unidentified speaker: Alpine Credits, where homeowners get it approved.
- 0:30
- Unidentified speaker: Can you make money in biotech?
- 0:32
- Unidentified speaker: Our guest says yes, and he has the receipts.
- 0:34
- Unidentified speaker: Three biotech stocks he likes got bought out this past year.
- 0:38
- Unidentified speaker: One sold for $10 billion.
- 0:40
- Unidentified speaker: Coming out why he says biotech's bull run is just getting started.
- 0:44
- Unidentified speaker: Why AI investors are piling into stocks like Moderna.
- 0:48
- Unidentified speaker: And six stocks he likes now.
- 0:49
- Unidentified speaker: Including the biggest winner of his career.
- 0:52
- Unidentified speaker: Let's get started.
- 0:52
- Unidentified speaker: This is Ticker Take.
- 1:00
- Unidentified speaker: Shopping again, Claire?
- 1:02
- Unidentified speaker: Shopping like Big Pharma.
- 1:03
- Unidentified speaker: Meaning?
- 1:04
- Unidentified speaker: When they want a hot new drug, they buy the company.
- 1:07
- Unidentified speaker: Hmm.
- 1:08
- Unidentified speaker: And lately they've been buying our guests' picks.
- 1:11
- Unidentified speaker: Eden Raheem of Next Edge Capital.
- 1:13
- Unidentified speaker: Welcome to Ticker Take.
- 1:14
- Unidentified speaker: Delighted to be here.
- 1:15
- Unidentified speaker: Thank you for having me here again.
- 1:17
- Unidentified speaker: And uh we're we're always pleased to have you, Eden, and uh and you gave some great perspective to our audience last time you were here.
- 1:23
- Unidentified speaker: And you feel we are in a new bull market for biotech.
- 1:26
- Unidentified speaker: How come?
- 1:27
- Unidentified speaker: Because we went through a very savage five and ten year period in biotech.
- 1:31
- Unidentified speaker: So biotech actually peaked back in the summer of 2015, had a series of rolling bear markets, had another peak in the COVID hype back in early 2021, fell 70% over the next four years, and it ended in a crescendo in April of 2025.
- 1:52
- Unidentified speaker: It recovered slowly out of there, but then has really tracked what typical bull markets for biotech has been over the past four decades, and along the way you get, you know, many 20-30% corrections, and we are in the midst of one of those right now.
- 2:07
- Unidentified speaker: So rates spiked, generalists ran away, and biotech went on sale.
- 2:13
- Unidentified speaker: Yeah, that's right.
- 2:14
- Unidentified speaker: And it's because biotech is very rate sensitive, like over its history, um, because it's a long-duration asset.
- 2:21
- Unidentified speaker: They invest heavily in the present in the hopes of generating a cash flow and a profitability in the years, many years ahead.
- 2:29
- Unidentified speaker: It's almost like a zero coupon bond, how it gets impacted by rising rates.
- 2:34
- Unidentified speaker: So biotech typically does poorly when rates are rising.
- 2:39
- Unidentified speaker: Now it when rates are stable, it does very well.
- 2:42
- Unidentified speaker: Okay, so stocks can go up, but they can also blow up.
- 2:46
- Unidentified speaker: So how do you avoid the blow-up?
- 2:48
- Unidentified speaker: Well, blow-ups are very characteristic of biotech.
- 2:51
- Unidentified speaker: It's it's just par for the course for it.
- 2:54
- Unidentified speaker: They uh go through a very long process, a decade-long process, of discovery in preclinical to filing an IND and getting it into human trials for safety, and then phase twos for efficacy, and then phase three to confirm the efficacy before they can get approval.
- 3:16
- Unidentified speaker: But along the way, they have all these risks that they have to overcome.
- 3:22
- Unidentified speaker: And each and any of those risks can cause a company to go down 70, 80, 90% in a day.
- 3:30
- Unidentified speaker: So it's like you're always navigating minefields.
- 3:33
- Unidentified speaker: Either your drug is potentially one of the best that's coming along, or you're just another Me Too company.
- 3:41
- Unidentified speaker: You have to be very disciplined to focus on the very narrow few that can overcome these risks and prevail to the end.
- 3:49
- Unidentified speaker: So coming up, uh, Eden's gonna walk us through six names that he's watching right now.
- 3:54
- Unidentified speaker: But first, a friendly reminder This is not financial advice.
- 3:57
- Unidentified speaker: Stock number one, cytokinetics.
- 3:59
- Unidentified speaker: Which makes a heart drug.
- 4:00
- Unidentified speaker: Yeah, and sales are off to a strong start, but the stock is back where it was a year ago.
- 4:04
- Unidentified speaker: Now, Eden, I think 90% of the analysts who cover the company like it.
- 4:07
- Unidentified speaker: They see big upside.
- 4:09
- Unidentified speaker: Do you think Big Pharma could go shopping here?
- 4:11
- Unidentified speaker: Yeah, I think so.
- 4:12
- Unidentified speaker: And they actually did approach a company three years ago.
- 4:16
- Unidentified speaker: So after they reported um very efficacious phase re data in obstructive HCM, uh, the stock surged from 35 where I was in uh to the mid-80s.
- 4:29
- Unidentified speaker: Rumors start to circulate that Novartis was looking at them and it surged to about 110.
- 4:35
- Unidentified speaker: Um subsequently, it came out that management was holding up for 145 and Novartis wouldn't budge, so the deal fell apart.
- 4:44
- Unidentified speaker: So you're looking at a company that um that is trading in the low 60s that had a takeover bid three years ago at 110 to 120.
- 4:57
- Unidentified speaker: So it makes you wonder like it's it's so de-risked at this level given all the subsequent positives that have come out for the company since that point.
- 5:08
- Unidentified speaker: Stock number two, Legend Biotech.
- 5:10
- Unidentified speaker: Legend makes a cancer treatment with Johnson Johnson.
- 5:13
- Unidentified speaker: It turns your own immune cells into cancer fighters, and this one's personal because my mom had a treatment like this.
- 5:19
- Unidentified speaker: Yeah, and Legend sales are on pace for $1.4 billion this year, and about 70% of analysts like it and see big upside.
- 5:26
- Unidentified speaker: Eden, so what's Wall Street missing?
- 5:29
- Unidentified speaker: Well, before we go on on Legend, I have a confession to make.
- 5:32
- Unidentified speaker: I have a serious character flaw, which is I'm almost incapable of being bearish on Legend.
- 5:37
- Unidentified speaker: I've done multiple round trips on it over the years.
- 5:41
- Unidentified speaker: Now, the stock is a value stock because of three key factors.
- 5:45
- Unidentified speaker: One is on the they're on a competitive side, which is um Gilead Acellus developed a similar car T that they're in they're gonna get approved for in fourth line.
- 5:55
- Unidentified speaker: And then Gilead acquired a Cellus for eight billion dollars.
- 5:59
- Unidentified speaker: Now remember, Legend's enterprise value is under three billion.
- 6:03
- Unidentified speaker: They'll be in fourth line, and the market's so worried about competition.
- 6:07
- Unidentified speaker: Well, most of Legend's sales are coming from second line.
- 6:11
- Unidentified speaker: So let let a Cellus and Gilead have fourth line.
- 6:15
- Unidentified speaker: You know what I mean?
- 6:17
- Unidentified speaker: It's so immaterial compared to it, but the market sort of magnified this entire effect.
- 6:22
- Unidentified speaker: Uh the second thing is uh Johnson ⁇ Johnson's Tech Vali plus Dara combination is treating patients in second line.
- 6:31
- Unidentified speaker: And so the market's looking at that and saying, oh, well, it has competition.
- 6:35
- Unidentified speaker: But but let's look at it this way: one and done treatment with unbelievable unprecedented five-year survival, versus tech validara, which is you're hospitalized for 48 hours, you get three injections in the first week, you get one injection every two weeks for the next 14, 16 weeks, you get one injection a week until week 25, and then you get one injection a month.
- 7:02
- Unidentified speaker: So you say to yourself, eh, which one do I want?
- 7:06
- Unidentified speaker: The one that already has proven five-year survival, one and done, or this process.
- 7:12
- Unidentified speaker: The third thing is there is another form of treatment that has really uh come to the fore.
- 7:19
- Unidentified speaker: It's called in vivo.
- 7:20
- Unidentified speaker: You can inject it, and this process occurs in the body.
- 7:23
- Unidentified speaker: Legend has a program like that, but earlier this year, a little private company called Kelowna reported phase one data in three patients that showed that their in vivo car T was effective, right?
- 7:37
- Unidentified speaker: So the entire world turned around and said, Oh wow, well, if we have in vivo car T, we don't need ex vivo car T anymore, right?
- 7:46
- Unidentified speaker: And they extrapolated that out.
- 7:48
- Unidentified speaker: And Lily came in and bought them for plus three billion dollars, plus another four billion in bio bucks.
- 7:54
- Unidentified speaker: So this private company with three patients treated got bought off plus three billion.
- 8:00
- Unidentified speaker: That's a market cap of legend right now.
- 8:03
- Unidentified speaker: Like the absurdity, I mean, the the Grand Canyon wide gap between Wall Street and KOL's is extraordinary.
- 8:12
- Unidentified speaker: Stock number three, TG Therapeutics.
- 8:14
- Unidentified speaker: Well, this company makes a multiple sclerosis drug.
- 8:17
- Unidentified speaker: Yes, and it's taking market share from Roche.
- 8:19
- Unidentified speaker: And 88% of the analysts who cover it, Eden, are fans of it.
- 8:22
- Unidentified speaker: They do see more upside.
- 8:24
- Unidentified speaker: And actually, you've talked with this one about us before, and it's done quite nicely since you first recommended it.
- 8:30
- Unidentified speaker: What's your take right now?
- 8:32
- Unidentified speaker: Well, I think the growth that started uh four years ago when they got approved will continue.
- 8:37
- Unidentified speaker: So it continues to grow nicely.
- 8:38
- Unidentified speaker: I mean, it's grown at basically 100% revenue growth every year for three years.
- 8:44
- Unidentified speaker: And uh there is an opportunity that's coming up to expand the market substantially.
- 8:49
- Unidentified speaker: Uh they'll be reporting uh subcutaneous dosing for uh Brium V.
- 8:55
- Unidentified speaker: What does that mean?
- 8:56
- Unidentified speaker: Uh it the injectable market.
- 8:58
- Unidentified speaker: Okay.
- 8:58
- Unidentified speaker: So right now, patients are treated every six months in a hospital setting with IV.
- 9:02
- Unidentified speaker: The sub Q version will allow you to administer at home, uh, which uh you know apparently 30% of the patients on in the MS market would would prefer at this point.
- 9:12
- Unidentified speaker: So it's a big market.
- 9:13
- Unidentified speaker: I got in um initially in the mid-teens in 2024, spring of 2024, and it just continued to be a champion.
- 9:21
- Unidentified speaker: You know, we've had you know 30% drawdowns a few times on it, but still I be.
- 9:26
- Unidentified speaker: Stock number four, which is Alpha Cognition.
- 9:28
- Unidentified speaker: Yeah, a small Canadian company with a new Alzheimer's drug.
- 9:31
- Unidentified speaker: Now, Alzheimer's has burned a lot of investors.
- 9:34
- Unidentified speaker: Uh, only a few analysts in this case cover the company, but Eden, they do like it.
- 9:38
- Unidentified speaker: Uh, what's your take on this company?
- 9:40
- Unidentified speaker: Yeah, it's it's the first approved drug in this form of uh drugs in Alzheimer's called acetylcholine esterase inhibitors.
- 9:49
- Unidentified speaker: And say that five times fast.
- 9:54
- Unidentified speaker: That is uh uh a drug that treats as symptoms due to Alzheimer's.
- 9:59
- Unidentified speaker: And what they did was uh there it's there are generic drugs, uh generic generic ACE inhibitors that um that they reformulated into a pro-drug.
- 10:10
- Unidentified speaker: And as a result of that, they have better side effect profile, better gastrointestinal, uh, better behavioral, better uh insomnia.
- 10:18
- Unidentified speaker: So we've seen um this very rapid growth.
- 10:22
- Unidentified speaker: Revenues in 2025 was about 10 million, revenues are gonna come in this year, about 25 million, next year at 55 million.
- 10:28
- Unidentified speaker: Now, on the horizon, they will have a sublingual version of this drug.
- 10:34
- Unidentified speaker: If they have a sublingual version, there's 30% of the Alzheimer's market that can't because swallowing is so difficult at that point.
- 10:43
- Unidentified speaker: So that is another huge market, but none of that's priced in stock.
- 10:47
- Unidentified speaker: Before our last two, Moderna.
- 10:49
- Unidentified speaker: It's been the elephant in the market this year.
- 10:51
- Unidentified speaker: It had a huge run-up.
- 10:54
- Unidentified speaker: Uh, and some of that was tied to AI.
- 10:57
- Unidentified speaker: Can you walk us through for people who need to understand the Moderna story, what's going on?
- 11:01
- Unidentified speaker: Sure.
- 11:02
- Unidentified speaker: So um, if you go back five years ago, uh in the Halcyon days and peak COVID, Moderna hit $500 a share and a market cap approaching $200 billion.
- 11:13
- Unidentified speaker: Then Icarus got too close to the sun and it fell 95% over those next five years down to $25 a share.
- 11:21
- Unidentified speaker: Short interest got to 70 million shares.
- 11:23
- Unidentified speaker: It was a more shorted SP 500 stock.
- 11:26
- Unidentified speaker: So massive short position on it.
- 11:29
- Unidentified speaker: And then came the results with Kitruda plus uh Intermarcin.
- 11:36
- Unidentified speaker: That's their their cancer vaccine.
- 11:38
- Unidentified speaker: The stock shot up because it was so heavily shorted, shot up from 60 to about $180 on a date.
- 11:43
- Unidentified speaker: So Moderna went to $180, did a big financing, pulled back to about $120.
- 11:48
- Unidentified speaker: Then a second Halo effect came in.
- 11:51
- Unidentified speaker: When generalists and AI investors discovered that Moderna would use AI to identify 34 neo antigens on a patient's cancer.
- 12:02
- Unidentified speaker: That buzz really captivated the imagination of AI investors.
- 12:07
- Unidentified speaker: Wow, a biotech company that's an AI company.
- 12:09
- Unidentified speaker: Off it went.
- 12:10
- Unidentified speaker: It went from 120 to 250.
- 12:12
- Unidentified speaker: So, what would be your message to people who are uh very much looking at Moderna because it's been on any everybody's radar this year?
- 12:19
- Unidentified speaker: I wouldn't buy it.
- 12:20
- Unidentified speaker: Okay.
- 12:20
- Unidentified speaker: I I think it's overvalued here.
- 12:22
- Unidentified speaker: I think the actual indication, Mal Noma indication that they're going after that partner with Katruda, is the market size is probably 20,000 patients, and they split the economics 50-50 with Merck.
- 12:33
- Unidentified speaker: So it's not a big indication.
- 12:35
- Unidentified speaker: It's probably a billion dollars a year in revenue for a company the size of what Moderna is now.
- 12:41
- Unidentified speaker: It really doesn't move the needle for them.
- 12:43
- Unidentified speaker: I can't imagine how it can go higher from here.
- 12:45
- Unidentified speaker: Stock number five, clear point in a row.
- 12:47
- Unidentified speaker: Okay, this is more med tech.
- 12:48
- Unidentified speaker: This company guides treatments deep into the brain.
- 12:51
- Unidentified speaker: Yeah, and the stocks had a bit of a roller coaster.
- 12:53
- Unidentified speaker: Only a few analysts cover it, but both of them like it and they see big upsides.
- 12:57
- Unidentified speaker: So, Eden, why do you like it?
- 12:59
- Unidentified speaker: So I've actually been involved with this company since 2017 at $2 a share.
- 13:03
- Unidentified speaker: It's a very innovative company.
- 13:05
- Unidentified speaker: What they do is they they have this device that just maps its way deep into the brain through which therapies can be delivered.
- 13:13
- Unidentified speaker: They have 10 core partners that are doing trials in um Huntington's, epilepsy, Parkinson's, Alzheimer's, but it's been anchored to that lightning rod company, Unicure Cure.
- 13:26
- Unidentified speaker: Unicure is going to get approved for Huntington's next year.
- 13:30
- Unidentified speaker: For every every procedure that Unicure does on a Huntington's patient, um ClearPoint stands to benefit $15,000 to $25,000.
- 13:41
- Unidentified speaker: So that is a $25 million a year revenue opportunity that's not priced on the stock at all.
- 13:49
- Unidentified speaker: But from 2027 on, they should return to about 20 20% top length growth looking out.
- 13:55
- Unidentified speaker: So I think it's a fantastic opportunity down here.
- 13:57
- Unidentified speaker: And stock number six, Nectar Therapeutics.
- 14:00
- Unidentified speaker: It's testing a new atopic dermatitis treatment.
- 14:03
- Unidentified speaker: And this is the biggest winner, Eden, of your career, uh, which we were teasing earlier.
- 14:08
- Unidentified speaker: Now I think more than 70% of the analysts do like the company.
- 14:12
- Unidentified speaker: But tell us a little bit about your journey with the stock, what the company is all about, and your take on it today.
- 14:17
- Unidentified speaker: Yeah, uh, so this is a company I was actually bearish on for a lot of my career.
- 14:22
- Unidentified speaker: And then uh pre-market on August 7th, 2023, this press release came across.
- 14:29
- Unidentified speaker: The stock was trading 200 million below net cash at the time.
- 14:33
- Unidentified speaker: So in pre-market, I bought up as much as I could um at that point, and so it's effectively after a consolidation of about six dollars a share that I paid for that position.
- 14:44
- Unidentified speaker: Going into phase two readout in June of last year, I almost never go into any phase two long company because the failure rate's 70 plus percent.
- 14:55
- Unidentified speaker: This was the only one I actually went in very long into.
- 14:58
- Unidentified speaker: They reported phase two efficacious uh atopic dermatitis data.
- 15:02
- Unidentified speaker: And it's a huge market.
- 15:03
- Unidentified speaker: Dupixen, which is a standard of care out there, is a $14 billion a drug year in in ATD.
- 15:09
- Unidentified speaker: And um, 30% of patients don't respond to Dupixent.
- 15:14
- Unidentified speaker: Respec is completely new, it's called a T Reg.
- 15:17
- Unidentified speaker: So you got into this company quite early or at a time when sentiment was extremely barren.
- 15:24
- Unidentified speaker: Yes.
- 15:25
- Unidentified speaker: Uh, and that's been a home run for you.
- 15:27
- Unidentified speaker: But are you saying you're still very much long the company right now?
- 15:30
- Unidentified speaker: I am.
- 15:30
- Unidentified speaker: The stock ran up to plus a hundred.
- 15:33
- Unidentified speaker: I sold a bunch up there, and then they did a big financing, and then it fell back into the 70s.
- 15:39
- Unidentified speaker: In alopecia, the standard of care right now is a jack inhibitor.
- 15:43
- Unidentified speaker: Very toxic, black box warning.
- 15:46
- Unidentified speaker: And if you stop taking it, all the benefits that you've seen for taking this toxic drug for years, you lose within months.
- 15:52
- Unidentified speaker: Right?
- 15:53
- Unidentified speaker: Nectar reported six-month off-drug data that showed the salt score below 20 was 63%.
- 16:01
- Unidentified speaker: So assault score below 20 is really good for an alopecia patient.
- 16:06
- Unidentified speaker: After six months of off-drug, they showed a rating of 63% of patients, which is unprecedented.
- 16:13
- Unidentified speaker: Right?
- 16:14
- Unidentified speaker: The standard of care right now is 20%.
- 16:16
- Unidentified speaker: They hit the stock on it because of the fact that the hush number was it was going to be 75%.
- 16:24
- Unidentified speaker: So in this market, in a correcting biotech market, if you do not exceed what the expectation is, they take you to the woodshed.
- 16:32
- Unidentified speaker: So right now the enterprise value for this company with two phase three drugs is 500 million.
- 16:37
- Unidentified speaker: So it just makes no sense to me.
- 16:38
- Unidentified speaker: I think it's an absolute buy here.
- 16:40
- Unidentified speaker: Before we let you go, Eden, we have one final question.
- 16:43
- Unidentified speaker: You joined us and talked about some companies last time that have since been acquired.
- 16:48
- Unidentified speaker: And I think something like 40 companies over your career that you've invested in have been acquired.
- 16:54
- Unidentified speaker: Of the companies we've talked about today, do you think any of them could be acquisition targets at the end of the day?
- 17:00
- Unidentified speaker: I I think so.
- 17:01
- Unidentified speaker: Um I think Big Pharma is facing something called a patent cliff.
- 17:05
- Unidentified speaker: So they have over $100 billion of revenues between now and 2030 that are gonna lose patent coverage that they need to replace.
- 17:14
- Unidentified speaker: There's a propensity for companies that um that Biopharma thinks will be billion plus drugs in the years ahead to get acquired.
- 17:23
- Unidentified speaker: So you look at something like uh TG Therapeutics, great growth trajectory, good visibility, um, potentially best in class and it's targeting drugs.
- 17:33
- Unidentified speaker: That's an important component for biopharm.
- 17:35
- Unidentified speaker: They like to acquire potentially best in class drugs because then they could build something around it, they can span it.
- 17:40
- Unidentified speaker: And the other thing is companies that develop their own trucally, not having licensed it in from someone else.
- 17:46
- Unidentified speaker: So that technology exists.
- 17:47
- Unidentified speaker: There's added value in that.
- 17:49
- Unidentified speaker: Eden, thank you so much for joining us again on Tick or Take.
- 17:52
- Unidentified speaker: It was delightful.
- 17:53
- Unidentified speaker: I'm glad to be here again.
- 17:54
- Unidentified speaker: Our thanks to Eden.
- 17:55
- Unidentified speaker: You can learn more about him in our description.
- 17:57
- Unidentified speaker: Hey, which of the six companies would you be interested in by?
- 18:00
- Unidentified speaker: Tell us in the comments.
- 18:01
- Unidentified speaker: And subscribe so you don't miss our next investing video.
- 18:03
- Unidentified speaker: See you next time.
- 18:18
- Unidentified speaker: The lights are twinkling.
- 18:20
- Unidentified speaker: The playlist is sparkling.
- 18:27
- Unidentified speaker: Canada's home for Christmas music with non-stop best of favorites 24-7.
- 18:34
- Unidentified speaker: Throughout the holidays, everywhere you go.
- 18:45
- Unidentified speaker: Or stream it anytime, anywhere on the Free IR Radio app.